0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Vitreous Band Formation and the Sustained-Release, Intravitreal Fluocinolone (Retisert) Implant FREE

Anat Galor, MD; Ron Margolis, MD; Peter K. Kaiser, MD; Careen Y. Lowder, MD, PhD
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2007;125(6):836-838. doi:10.1001/archopht.125.6.836.
Text Size: A A A
Published online

The fluocinolone acetonide implant (Retisert; Bausch & Lomb, Rochester, NY) is a sustained-release, intravitreal steroid implant developed to treat chronic noninfectious uveitis.1 Two, 3-year, phase 3, randomized, multicenter clinical trials have demonstrated a statistically significant decrease in the recurrence of uveitis and the need for additional corticosteroids or other immunosuppressive agents after implantation.2

During these studies, 50% to 90% of patients experienced an adverse event after implantation, most commonly cataract formation and increased intraocular pressure.2 Within 2 years of implantation, nearly 100% of phakic eyes required cataract surgery and one third of patients required a glaucoma surgical procedure. Other adverse events included ptosis, eyelid edema, conjunctival hemorrhage, chemosis, corneal edema, vitreous opacities, vitreous hemorrhage, macular edema, retinal hemorrhage, hypotony, and choroidal detachment.2 We describe 4 patients with an adverse ocular event not previously described after Retisert implantation: the formation of vitreous bands from the posterior pole to the implant.

METHODS

A retrospective medical chart review of patients who received a Retisert implant at the Cole Eye Institute, Cleveland, Ohio, was conducted. Inclusion criteria included patients with clinically visible vitreous bands extending from the posterior pole to the Retisert implant. We defined vitreous bands as bandlike or sheetlike opacities in the vitreous that appear denser than typical inflammatory vitreous condensations and extend from the posterior pole to the implant. Data collected from the medical chart included surgical techniques and complications, uveitis control, best-corrected Snellen visual acuity (BCVA) before and after implant insertion and after documentation of vitreous bands, and the need for additional surgical procedures.

RESULTS

Of the 33 patients who received the Retisert implant, 4 (12%) developed vitreous bands that were visible on clinical examination.

Case 1

A 46-year-old white woman received an implant in her left eye for idiopathic uveitis. Prior therapies included posterior sub-Tenon triamcinolone injections and oral cyclosporine. Repositioning of the implant was required 1 month after implantation for slight extrusion of the suture tab. The BCVA improved from 20/80 to 20/70 OS and intraocular inflammation was controlled without the need for local or systemic immunosuppressive medication. A trabeculectomy and cataract extraction were performed after 3 and 8 months, respectively, with visual improvement in her visual acuity to 20/50 OS. Two years after implantation, the patient experienced recurrences of inflammation and was treated with local corticosteroids. Three and a half years following initial implantation, thick vitreous bands were noted from the posterior pole to the implant (Figure 1) causing decreased visual acuity to 20/200. A pars plana vitrectomy and membrane peel were performed and the depleted implant was replaced. A posterior vitreous detachment was noted to be present at the time of surgery. The postoperative vision improved to a visual acuity of 20/70 with a decrease in inflammation.

Place holder to copy figure label and caption
Figure 1.

Vitreous bands are seen in the anterior vitreous converging to the inferotemporal fluocinolone acetonide implant (Retisert implant; Bausch & Lomb, Rochester, NY) (not seen).

Graphic Jump Location
Case 2

A 55-year-old white woman received an implant in her left eye for idiopathic uveitis. Prior systemic medications included prednisone, cyclophosphamide, and mycophenolate mofetil. After implant, BCVA improved from 20/40 to 20/25 OS and intraocular inflammation was controlled without systemic immunosuppression. Three years later, the implant was exchanged owing to increasing inflammation. The patient developed steroid-induced ocular hypertension requiring an Ahmed tube implant; BCVA was stable at 20/50. One year after reimplantation, a thick epiretinal membrane (ERM) was noted with vitreous bands extending to the implant, decreasing visual acuity to 20/200 OS. The patient underwent pars plana vitrectomy and membrane peel. A posterior vitreous detachment was created at the time of surgery. Six months later, vision improved to a visual acuity of 20/50 and inflammation was controlled.

Case 3

A 57-year-old white woman received an implant in her left eye for idiopathic uveitis. Prior therapies included posterior sub-Tenon injections and oral prednisone. Repositioning of the implant was required 1 month after implantation for slight extrusion of the suture tab. The patient's inflammation was controlled without oral and topical prednisone with BCVA improving from 20/40 to 20/30 OS. Four and a half years after implantation, vitreous bands were noted extending from the posterior pole to the implant (Figure 2A), decreasing visual acuity to 20/50. Optical coherence tomography revealed vitreomacular traction (Figure 2B).

Place holder to copy figure label and caption
Figure 2.

A, Color fundus photograph of the left eye (case 3) demonstrates thick, vitreous bands overlying retinal vessels. B, Optical coherence tomography of the left macula reveals loss of foveal contour due to traction by vitreous bands.

Graphic Jump Location
Case 4

A 49-year-old white man received an implant in his left eye for idiopathic uveitis. Prior therapy included posterior sub-Tenon injections, intravitreal triamcinolone injections, and systemic methotrexate. The implant procedure was complicated by a dense vitreous hemorrhage and a small choroidal hemorrhage at the insertion site. After resolution of the hemorrhage, BCVA was slightly worse (20/40) than the patient's baseline (20/25). The patient's inflammation was well controlled after implantation. Six months after implantation, a vitreous band was noted from the posterior pole to the implant (Figure 3) with no decrease in vision.

Place holder to copy figure label and caption
Figure 3.

Slitlamp photograph of the left eye showing vitreous bands (arrow) connecting to the fluocinolone acetonide implant (Retisert implant; Bausch & Lomb; Rochester, NY [asterisk]).

Graphic Jump Location

COMMENT

Vitreous band formation (sheetlike opacities in the vitreous appearing denser than typical inflammatory vitreous condensations) extending from the posterior pole to the Retisert implant is a complication that, to our knowledge, is not yet described in the literature. This complication was not noted in the 227 patients included in the original Retisert studies; however, these patients were followed for only 3 years and most of the patients in our study developed vitreous bands more than 3 years after implant placement. Vitreous bands were associated with a decrease in vision in 3 patients secondary to vitreous opacities and vitreomacular traction. In the 2 patients who underwent surgery to release this traction, an improvement in BCVA was seen.

Ocular inflammation and vitreous hemorrhage are known risk factors for ERM formation. While our patients with uveitis may have developed an ERM irrespective of implant placement, the appearance and directionality of the bands described is different from a typical ERM that extends tangentially across the posterior pole. Vitreous bands associated with the Retisert implant are more prominent and stretch in an axial direction, from the posterior pole to the implant. The etiology of vitreous bands is likely multifactorial. In the first 3 patients, depletion of steroid in the implant led to recurrence of inflammation, and the presence of a foreign body may have incited the formation of vitreous bands to the implant. A perioperative vitreous hemorrhage was most likely the main contributor to band formation in patient 4. Because the explanted material was not sent for pathologic examination, we do not have information on the histological characteristics of the vitreous bands.

In conclusion, Retisert implant placement may lead to the formation of vitreous bands. When vitreous bands cause visually significant traction, patients may benefit from vitreoretinal surgery. In addition, the surgical procedure for implant removal or exchange in patients with clinically visible vitreous bands should be modified to include a complete vitrectomy in order to avoid retinal traction at the time of implant removal.

ARTICLE INFORMATION

Correspondence: Dr Lowder, Cleveland Clinic Cole Eye Institute, 9500 Euclid Ave, Desk i32, Cleveland, OH 44195 (lowderc@ccf.org).

Financial Disclosure: Dr Kaiser is on the Scientific Advisory Board of Bausch & Lomb.

Funding/Support: Cole Eye Institute, employer of Drs Lowder and Kaiser, received research grant support from Bausch & Lomb, Rochester, NY.

REFERENCES

Jaffe  GJMcCallum  RMBranchaud  BSkalak  CButuner  ZAshton  P Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;1121192- 1198
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Vitreous bands are seen in the anterior vitreous converging to the inferotemporal fluocinolone acetonide implant (Retisert implant; Bausch & Lomb, Rochester, NY) (not seen).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

A, Color fundus photograph of the left eye (case 3) demonstrates thick, vitreous bands overlying retinal vessels. B, Optical coherence tomography of the left macula reveals loss of foveal contour due to traction by vitreous bands.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Slitlamp photograph of the left eye showing vitreous bands (arrow) connecting to the fluocinolone acetonide implant (Retisert implant; Bausch & Lomb; Rochester, NY [asterisk]).

Graphic Jump Location

Tables

References

Jaffe  GJMcCallum  RMBranchaud  BSkalak  CButuner  ZAshton  P Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;1121192- 1198
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,335 Views
9 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference